Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Receivables (2021 - 2022)

Solid Biosciences' Change in Receivables history spans 2 years, with the latest figure at -$14000.0 for Q2 2022.

  • For Q2 2022, Change in Receivables fell 333.33% year-over-year to -$14000.0; the TTM value through Dec 2022 reached -$110000.0, down 200.0%, while the annual FY2022 figure was -$110000.0, 200.0% down from the prior year.
  • Change in Receivables for Q2 2022 was -$14000.0 at Solid Biosciences, up from -$96000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $308000.0 in Q3 2021 and bottomed at -$484000.0 in Q4 2021.